The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
生物技術未來一週（5月8日至14日）：Bausch Health 頭條中型股收益、Veru 的歐盟前會議、會議演講等
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:IBB), considered a proxy for the sector, shed close to 3 percent during the week.
在美聯儲加息50個基點之後，受宏觀經濟擔憂的拖累，生物科技股在截至5月6日的一週內再次下跌。那個 iShares 生物技術交易所買賣基金 納斯達克股票代碼：IBB）被認爲是該行業的代表，本週下跌了近3％。
Penny stock and digital therapeutics company Better Therapeutics, Inc. (NASDAQ:BTTX) more than doubled despite a lack of any meaningful catalysts. On the other hand, Connect Biopharma Holdings Limited (NASDAQ:CNTB) lost more than half its market value after its investigational asset that is being evaluated for ulcerative colitis flunked a mid-stage trial.
Penny stock 和數字療法公司 Better Therapeutics 納斯達克股票代碼：BTTX）儘管缺乏任何有意義的催化劑，但翻了一番多。另一方面， Connect 生物製藥控股有限公司 納斯達克股票代碼：CNTB）在接受潰瘍性結腸炎評估的研究資產在中期試驗失敗後，其市值損失了一半以上。
Earnings news flow...
財報新...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。